Treatment of non-insulin-dependent diabetes mellitus

Expert Opinion on Investigational Drugs

Volumn 12, Issue 4, 2003, Pages 623-633

  Patel, Mona ^a   Rybczynski, Philip J ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Adult onset; DPP IV; GSK3; Hyperglycemia; Insulin sensitiser; NIDDM; PPAR; RXR; SGLT; Type II diabetes mellitus

Indexed keywords

2 BENZYLPHENYL BETA GLUCOPYRANOSIDE DERIVATIVE; 3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; 4 [4 [3 (4 ACETYL 3 HYDROXY 2 PROPYLPHENOXY)PROPOXY]PHENOXY]ACETIC ACID; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; 6 [[2 [[2 (2 CYANO 1 PYRROLIDINYL) 2 OXOETHYL]AMINO]ETHYL]AMINO]NICOTINONITRILE; AGN 194204; ANTIDIABETIC AGENT; CP 320626; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ENZYME INHIBITOR; GLUCOSE; GLUCOSE TRANSPORTER INHIBITOR; GLYCOGEN PHOSPHORYLASE INHIBITOR; GW 0791; GW 7282; LG 101506; LR 90; NETOGLITAZONE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PIOGLITAZONE; PROPIOPHENONE DERIVATIVE; PROTEIN TRYOSINE PHOSPHATASE 1B INHIBITOR; PYRANOSIDE; RETINOID X RECEPTOR AGONIST; ROSIGLITAZONE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN;

AMPUTATION; BLINDNESS; CARDIOVASCULAR DISEASE; CHEMISTRY; CLINICAL TRIAL; DIABETES MELLITUS; DIET; DRUG ABSORPTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG STRUCTURE; DRUG TARGETING; EPIDEMIC; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY INJURY; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; RETROSPECTIVE STUDY; REVIEW; WORLD HEALTH ORGANIZATION;

ANIMALS; DIABETES MELLITUS, TYPE 2; ENZYME INHIBITORS; HUMANS; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; TRANSCRIPTION FACTORS;

EID: 0037397978     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.12.4.623     Document Type: Review

References (66)

1. World Health Organization: Prevention of Diabetes Mellitus. (1994) (Report 884).
2. World Health Organization Global burden of diabetes mellitus. (1998) (Press Release WHO/63).
3. LIU KG, LAMBERT MH, AYSCUE AH et al.: Synthesis and biological activity if L-tyrosine-based PPARgamma agonists with reduced molecular weight. Bioorg. Med. Chem. Lett. (2001) 11(24):3111-3113.
4. LIU KG, LAMBERT MH, LEESNITZER LM et al.: Identification of a series of PPARgamma/delta dual agonists via solid-phase parallel synthesis. Bioorg. Med. Chem. Lett. (2001) 11(22):2959-2962.
5. HDL Cholesterol. Second Annual Meeting, Metabolic Pathways and Drug Development, Boston, MA, USA (2001).
6. BERGMAN JP, HAN W, METZGER E et al.: Discovery of novel arylthiazolidinedione derivatives as selective PPARgamma agonists for the treatment of Type II diabetes mellitus. 221st American Chemical Society National Meeting, San Diego, CA, USA (2001):MEDI 240.
7. BOUERES JK, HAN W, SANTINI C et al.: Novel class of aryl thiazolidinedione PPAR agonists as insulin sensitizing agents for the treatment of Type II diabetes mellitus. 221st American Chemical Society National Meeting, San Diego, CA, USA (2001): MEDI 241.
8. ZEILLER JJ, BRUNET M, BERTELON JJ et al.: LR90, A new compound with both hypolipidemic and hypoglycemic activities. 220th American Chemical Society National Meeting, Washington DC, USA (2000):MEDI 308.
9. MURAKAMI K, TOBE K, IDE T et al.: A novel sensitizer acts as a coling for peroxisome proliferator-activated receptor-alpha (PPAR-alpha) and PPAR-gamma. Effects of PPAR-alpha activation on abnormal lipid metabolism in liver of Zucker Fatty rats. Diabetes (1998) 47(12):1841-1847.
10. WULFF EM, JEPPESEN L, BURY PS et al.: Characterisation of a future generation insulin sensitizers in vitro and in vivo. Diabetes (2001) 50(Suppl. 6):2210.
11. IDE T MURAKAMI K, TSUNODA M, MOCHIZUKI T KADOWAKI T: KRP-297 improves impaired fatty acid oxidation in skeletal muscles and livers of Zucker diabetic fatty rats. Diabetologia (1999) 42(Suppl. 1):50.
12. MERCK & CO.: Annual report 1999 (March 07, 2000).
13. LIGAND PHARMACEUTICALS, INC.: Company presentation (2001).
14. BROOKS DA, ETGEN GJ, RITO CJ et al.: Design and synthesis of 2-methyl-2-[4-(2-[5-methyl-2-aryloxazol-4-yl] ethoxy)phenoxy]propionic acids: a new class of dual PPARalpha/gamma agonists. J. Med. Chem. (2001) 44(13):2061-2064.
15. SORBERA LA, CASTANER M, SILVESTRE J: Netoglitazone. Drugs Future (2002) 27(2): 132-229.
16. ISHII S, WASAKI M, OHE T, UENO H, TANAKA H: MCC-555: A highly potent thiazolidinedione lacking hematological and cardiac side-effects. Diabetes (1996) 45(Suppl. 2):141.
17. UPTON R, WIDDOWSON PS, KADOWAKI S, WILLIAMS G: Improved insulin sensitivity in Zucker and ZDF rats following chronic treatment with novel thiazolidinedione MCC-555. Br. J. Pharmacol. (1997) 122(Proc. Suppl.):149P.
18. SAUERBERG P, PETTERSSON I, JEPPESEN L et al.: Novel tricyclic-alkoxphenylpropionic acids. Dual PPAR/ agonists with hypolipidemic and antidiabetic activity. J. Med. Chem. (2002) 45(4):789-804.
19. YANAGISAWA H, TAKAMURA M, YAMADA E et al.: Novel oximes having 5-benzyl-2,4-thiazolidinedione as antihyperglycemic agents: synthesis and structure-activity relationship. Bioorg. Med. Chem. Lett. (2000) 10(4):373-375.
20. OGUCHI M, WADA K, HONMA H et al.: Molecular design, synthesis, and hypoglycemic activity of a series of thiazolidine-2,4-diones. J. Med. Chem. (2000) 43(16):3052-3066.
21. DELMAS EB, LASSALLE I, SARDON V et al.: Conception, synthesis and pharmacological evaluation of PPAR(s) gamma ligands. Drug Future (2002) 27(Suppl. A):P491.
22. DEL CASTILLO JC, MOURELLE M, HUGUET J, CABRE F: Synthesis and biological activity of novel thiazolidine-2,4-diones series with potent antihyperglycemic and antihyperlipidemic oral activities. Drugs Future (2002) 27(Suppl. A):P209.
23. MUKHERJEE R, DAVIES PJ, CROMBIE DL et al.: Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature (1997) 386:407-410.
24. MICHELLYS PY et al.: RXR modulators. Design, synthesis and hypoglycaemic activity of new RXR-selective locked-dienoic acids. 223rd American Chemical Society National Meeting, Orlando, FL, USA (2002):MEDI-004.
25. MILLER AB, LENHARD JM, XU HE et al.: Structure based design of a potent RXR agonist. 223rd American Chemical Society National Meeting, Orlando, FL, USA (2002):MEDI-006.
26. VULIGONDA V, THATCHER SM, CHANDRARATNA RA: Enantioselective syntheses of potent retinoid X receptor ligands: Differential biological activities of individual antipodes. J. Med. Chem. (2001) 44:2298-2303.
27. MURRAY A, HANSEN JB, CHRISTENSEN BV: A novel synthesis of 9-cis-retinoic acid tagretin analogues via Pauson-Khand or Heck reaction. Tetrahedron (2001) 57:7383-7390.
28. OKU A, UETA K, ARAKAWA K et al.: Antihyperglycemic effect of T-1095 via inhibition of renal Na+-glucose cotransporters in streptozotocin-induced diabetic rats. Biol. Pharm. Bull. (2000) 23:1434-1437.
29. CHEN X, CONWAY BR, ERICKSON E, DEMAREST KT: RWJ394718 (T-1095), an inhibitor of sodium-glucose cotransporters increases urinary glucose excretion in Zucker diabetic fatty (ZDF) rats. Diabetes (2001) 50(Suppl. 2):2153.
30. JENS J, DEACON CF: Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for Type 2 diabetes. Diabetes (1998) 47:1663-1670.
31. VILLHAUER EB, BRINKMAN JA. NADERI GB et al.: 1-[2-[(5-Cyanopyridin-2-yl) amino]ethylamino]acety-2-(S)-pyrrolidine-carbonitrile: A potent, selective, and orally bioavailable dipeptidyl peptidase IV Inhibitor with antihyperglycemic properties. J. Med. Chem. (2002) 45:2362-2365.
32. HOLMES D: DPP-IV inhibitors and Type 2 diabetes. SMi Conference - Diabetes (2002).
33. AHRN B, SIMONSSON E, EFENDIC J et al.: Inhibition of DPP-IV by NVP-DPP-728 improves metabolic control over a 4 week period in Type 2 diabetes. Diabetes (2001) 50(Suppl. 1):416.
34. ROTHENBERG P, KALBAG J, SMITH H, GINGERICH R, NEDELMAN J: Treatment with a DPP-IV inhibitor, NVP-DPP-728, increases prandial intact GLP-1 levels and reduces glucose exposure in humans. Diabetes (2000) 49(Suppl. 1):39.
35. NOVARTIS R&D DAY: Company presentation (2001).
36. NOVARTIS R&D DAY: Company presentation (2002).
37. FREYSE E, BERG S, HEINKE P et al.: Glucose metabolism in diabetic zacker fatty rats (ZR) during chronic oral therapy by the DP IV inhibitor P32/98. Diabetes (2000) 49(Suppl. 1):1808.
38. DEMUTH H, HOFFMAN T, GLUND K et al.: Single dose treatment of diabetic patients by the DP IV inhibitor P32/98. Diabetes (2000) 49(Suppl. 1):413.
39. DEMUTH H, HOFFMAN T, GLUND K et al.: Single dose treatment of diabetic patients by DP IV inhibitor P32/98. Diabetes (2000) 49(Suppl. 1).
40. GLUND K, HOFFMAN T, DEMUTH H et al.: Single dose-escalation study to investigate the safety and tolerability of the DP IV inhibitor P32/98. Diabetes (2000) 49(Suppl. 1).
41. DEMUTH H: Development of PS32/98. SMi Conference - Diabetes (2002).
42. SUDRE B, BROQUA P. WHITE RB et al.: Chronic inhibition of circulating dipeptidyl peptidase IV by FE-999011 delays the occurrence of diabetes in male zucker diabetic fatty rats. Diabetes (2002) 51:1461-1469.
43. NAKAJIMA T et al.: 22nd Symposium Medicinal Chemistry Shizuoka, Japan (2002) (Abstract 2P-06).
44. KANSTRUP A, BRANNER S, CARR RD, CHRISTIANSEN LB, ELM T, RIBEL U: A structurally novel dipeptidyl peptidase IV inhibitor. 7-Benzyl-1,3-dimethyl-8-piperazinoxanthine. 28th National Medicinal Chemistry Symposium, San Diego, CA, USA (2002).
45. TREADWAY JL, MENDYS P, HOOVER DJ: Glycogen phosphorylase inhibitors for the treatment of Type 2 diabetes mellitus. Expert Opin. Investig. Drugs (2001) 10(3):439-454.
46. HOOVER DJ, MARTIN WH, TREADWAY JL et al.: Indole-2-carboxamide inhibitors of human liver glycogen phosphorylase. J. Med. Chem. (1998) 41:2934-2938.
47. LUNDBECK JM, JAKOBSEN P, KRISTIANSEN M, WESTERGAARD N, ANDERSEN B, IVERSEN L: Novel [2-(benzoylamino)-phenoxy]-phthalic acid derivatives as potent hepatic glycogen phosphorylase inhibitors. 17th International Symposium on Medicinal Chemistry, Barcelona, Spain (2002): P347.
48. BERGANS N, STALMANS W, GOLMANN S, VANSTAPEL F: Molecular mode of inhibition of glycogenolysis in rat liver by the dihydropyridine derivative, BAY R3401: inhibition and inactivation of glycogen phosphorylase by an activated metabolite. Diabetes (2000) 49(9):1419-1426.
49. EVANS JL, BAHIJA J: Protein tyrosine phosphatases: their role in insulin action and potential as drug targets. Expert Opin. Investig. Drugs (1999) 8(2):139-160.
50. BLASKOVICH MA, KIM HO: Recent discovery and development of protein tyrosine phosphatase inhibitors. Expert Opin. Ther. Patents (2002) 12(6):871-905.
51. HANSEN TK, IVERSON LF, LAU J et al.: Potent non-peptide protein-tyrosine phosphatase inhibitors. 223rd American Chemical Society National Meeting, Orlando, FL, USA (2002): MEDI 003.
52. ANDERSON HS, OLSEN OH, IVERSON LF et al.: Discovery and SAR of a novel selective and orally bioavailable non-peptide classical competitive inhibitor class of protein-tyrosine phosphatase 1B. J. Med. Chem. (2002) 45(20):4443-4459.
53. PEI Z: 61st American Diabetes Association-Scientific Sessions, Philadelphia, PA, USA (2001).
54. PEI Z, ZINKER BA, GUM RJ et al: (2R)-2-(2′,6′-dichloro-4′-dibenzo (b,d)furan-4′-ylphenoxy)-3-phenylpropanoic acid (A-321842) as a protein tyrosine phosphatase 1B (PTP1B) inhibitor with anti-diabetic effects in ob/ob mice. Diabetes (2001) 50(Suppl. 6):1524.
55. MALAMAS MS, SREDY J, GUNAWAN I et al.: New azolidinediones as inhibitors of protein tyrosin phosphatase 1B with antihyperglycemic properties. J. Med. Chem. (2000) 43(5):995-1010.
56. MALAMAS MS, SREDY J, MOXHAM C et al.: Novel benzofuran and benzothiophene biphenyls as inhibitors of protein tyrosine phosphatase 1B with antihyperglycemic properties. J. Med. Chem. (2000) 43(7):1293-1310.
57. KAIDANOVICH O, ELDAR-FINKELMAN H: The role of glycogen synthase kinase-3 in insulin resistance and Type 2 diabetes. Expert. Opin. Ther. Targets (2002) 6(5):555-561.
58. MARTINEZ A, CASTRO A, DORRONSORO I, ALONSO M: Glycogen synthase kinase 3 (GSK 3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev. (2002) 22(4):373-384.
59. HENRIKSEN EJ, JOHNSON KW, KINNICK TR, O'KEEFE MP, HARRISON SD: Oral treatment of glycogen synthase kinase-3 inhibitor improves glucose tolerance and skeletal muscle glucose transport activity in zucker diabetic fatty rats. Diabetalogia (2001) 44(Suppl. 1):681.
60. CLINE GW, JOHNSON K, REGITTNIG W et al.: Effects of a novel glycogen synthase kinase-3 inhibitor on insulin stimulated glucose metabolism in ZDF (fa/fa) rats. Diabetes (2002) 50(2):1281.
61. CLINE GW, JOHNSON K, REGITTNIG W, PERRET P: Effects of novel glycogen synthase-3 (GSK-3) inhibitor on liver and muscle glycogen synthesis in awake ZDF (fa/fa) diabetic rat. Diabetes (2001) 51(Suppl. 6):1350.
62. SAMUELS I, LOW C, FAWCETT K et al.: Efficacy and pharmacological properties of novel glycogen synthase kinase-3 (GSK-3) inhibitors in rodent models of Type 2 diabetes. Diabetes (2001) 50(Suppl. 6):1352.
63. BOWLER AN, KILBURN JP, ENGLEHARDT S, DANIELSEN GM, KURTZHALS P: Novel substituted oxadiazepines with glucose lowering properties. 16th International Symposium of Medicinal Chemistry, Bologna, Italy (2000):PA 9.
64. Novo Nordisk A/S. Drug report of GSK-3 inhibitors. IDdb3 report (2002).
65. HAIGH D et al.: 12th Symposium on Medicinal Chemistry Hatfield, UK (2001).
66. COUGHLAN MP, CULBERT AA, CROSS DAE et al.: Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol. (2000) 7(10):793-803.